SRR33532763
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.340
- WNT_BETA_CATENIN_SIGNALING+0.320
- APICAL_JUNCTION+0.270
- NOTCH_SIGNALING+0.270
- MYOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- MITOTIC_SPINDLE+0.210
- MYC_TARGETS_V2+0.180
- ANGIOGENESIS+0.110
- TGF_BETA_SIGNALING+0.100
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.350
- MYC_TARGETS_V1-0.320
- ALLOGRAFT_REJECTION-0.280
- MTORC1_SIGNALING-0.280
- PROTEIN_SECRETION-0.250
- ANDROGEN_RESPONSE-0.210
- E2F_TARGETS-0.210
- FATTY_ACID_METABOLISM-0.210
- KRAS_SIGNALING_UP-0.210
- ESTROGEN_RESPONSE_LATE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303772 | — | — | 0.807 |
| 2 | SRR8613760 | — | E | 0.795 |
| 3 | c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56 | — | — | 0.766 |
| 4 | MBCProject_0832_T1_RNA | — | A | 0.762 |
| 5 | SRR4195667 | — | — | 0.757 |
| 6 | SRR1313107 | — | F | 0.748 |
| 7 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.744 |
| 8 | SRR17866843 | — | — | 0.744 |
| 9 | TCGA-4H-AAAK-01A-12R-A41B-07 | — | A | 0.744 |
| 10 | SRR8613780 | — | E | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |